Journals / Çukurova Anestezi ve Cerrahi Bilimler Dergisi / 2025 / Cilt: 8 Sayı: 4

Rapid Improvement of Fatigue and Sleep in Active Rheumatoid Arthritis with Anti-TNF Therapy: A Retrospective Observational Study

Aktif Romatoid Artrit Hastalarında Anti-TNF Tedavisiyle Yorgunluk ve Uyku Düzeyinin Hızlı İyileşmesi: Retrospektif Gözlemsel Bir Çalışma

Bora Uzuner(ONDOKUZ MAYIS ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0001-9498-0289
Sertaç Ketenci(ONDOKUZ MAYIS ÜNİVERSİTESİ, TIP FAKÜLTESİ, FİZİKSEL TIP VE REHABİLİTASYON ANABİLİM DALI / ROMATOLOJİ BİLİM DALI)0000-0002-2950-8778
Ender Salbaş(BALIKESİR ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0001-7460-2889
Ayhan Bilgici(ONDOKUZ MAYIS ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-7854-314X
Pages
464–468
Publication Date
2025-12-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Keywords: rheumatoid arthritis, anti-TNF therapy, fatigue, sleep quality,

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Patients with rheumatoid arthritis (RA) suffer from high burdens of fatigue and poor sleep quality which persist even when joint inflammation is controlled.
📊
Key Findings & Data:We aimed to retrospectively evaluate the 3-month impact of initiating anti-TNF therapy initiation on fatigue sleep quality and functional status in patients with active RA.
💡
Conclusion & Impact:Keywords: rheumatoid arthritis, anti-TNF therapy, fatigue, sleep quality,
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:romatoid artrit · Anti-TNF Tedavi · Yorgunluk

Abstract

Objective: Patients with rheumatoid arthritis (RA) suffer from high burdens of fatigue and poor sleep quality which persist even when joint inflammation is controlled. We aimed to retrospectively evaluate the 3-month impact of initiating anti-TNF therapy initiation on fatigue sleep quality and functional status in patients with active RA. Methods: We conducted a 3-month single-center retrospective cohort study reviewing the records of 39 patients with active RA (Disease Activity Score 28 [DAS28] > 5.1) despite stable csDMARDs. A matched group of 36 healthy controls was used for baseline comparisons. Patients had initiated adalimumab, etanercept, or infliximab. Assessments had been performed at baseline and 3 months using the DAS28 (disease activity), Health Assessment Questionnaire (HAQ), Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), Pittsburgh Sleep Quality Index (PSQI), and Beck Depression Inventory (BDI). 31 patients had completed the 3-month follow-up and had complete data for analysis. Results: At 3 months, patients showed significant clinical improvement. Mean DAS28 decreased from 5.5 ± 1.2 to 3.3 ± 1.6 (p < 0.001) and 39% (12/31) achieved remission. Significant improvements were seen in patient-reported outcomes. The mean MFSI-SF total fatigue score decreased from 27.6 to 10.4 (p < 0.001) and the mean global PSQI score improved from 9.5 to 7.0 (p < 0.001). Functional status (HAQ) and depressive symptoms (BDI) also improved significantly (both p < 0.001). At baseline, fatigue strongly correlated with poor sleep (r=0.626), depression (r=0.674), and HAQ (r=0.656). Improvement in fatigue correlated moderately with improvement in depression (Δ-BDI r=0.571). Conclusion: Anti-TNF therapy provides rapid and significant improvements not only in clinical disease activity but also in the key patient-reported burdens of fatigue, sleep quality, and depression within three months of initiation. Keywords: rheumatoid arthritis, anti-TNF therapy, fatigue, sleep quality,

Özet

Amaç: Romatoid artrit (RA) hastaları, eklem inflamasyonu kontrol altına alınsa bile genellikle devam eden şiddetli yorgunluk ve bozulmuş uyku kalitesi ile yaşam kalitesi kaybı yaşarlar. Bu çalışmada, aktif RA’lı hastalarda Anti-TNF tedavisinin başlanmasından sonraki üç aylık dönemde yorgunluk, uyku kalitesi ve fonksiyonel durum üzerindeki etkileri retrospektif olarak değerlendirmek amaçlanmıştır. Yöntem: Tek merkezli, 3 aylık retrospektif kohort çalışmasında, stabil klasik DMARD (csDMARD) tedavisine rağmen aktif hastalığı devam eden (DAS28 > 5.1) toplam 39 RA hastasının kayıtları incelendi. Karşılaştırma amacıyla yaş ve cinsiyet açısından eşleştirilmiş 36 sağlıklı birey kontrol grubu olarak kullanıldı. Hastalar adalimumab, etanersept veya infliksimab tedavisine başlanmıştı. Değerlendirmeler tedavi öncesi ve 3. ayda yapılmış olup şu ölçekler kullanıldı: DAS28 (hastalık aktivitesi), HAQ (fonksiyonel yetersizlik), MFSI-SF (yorgunluk), PSQI (uyku kalitesi) ve BDI (depresyon düzeyi). Toplam 31 hasta, 3 aylık izlemi tamamlamış ve analiz için eksiksiz veriye sahipti. Bulgular: Üçüncü ay sonunda hastalarda belirgin klinik düzelme saptandı. Ortalama DAS28 skoru 5.5 ± 1.2’den 3.3 ± 1.6’ya geriledi (p < 0.001) ve hastaların %39’u remisyona ulaştı. Yorgunluk (MFSI-SF) toplam skoru 27.6’dan 10.4’e, uyku kalitesi (PSQI) toplam skoru 9.5’ten 7.0’a iyileşti (her ikisi de p < 0.001). Fonksiyonel durum (HAQ) ve depresyon (BDI) skorlarında da anlamlı düzelme izlendi (her ikisi p < 0.001). Başlangıçta yorgunluk, kötü uyku (r=0.626), depresyon (r=0.674) ve HAQ skorlarıyla (r=0.656) güçlü korelasyon gösterdi. Yorgunluktaki düzelme, depresyondaki düzelme ile orta düzeyde ilişkiliydi (Δ-BDI r=0.571). Sonuç: Anti-TNF tedavisi, yalnızca klinik hastalık aktivitesinde değil, aynı zamanda hastalar tarafından bildirilen önemli yaşam kalitesi parametrelerinde özellikle yorgunluk, uyku kalitesi ve depresyonda 3 ay gibi kısa bir sürede belirgin ve hızlı iyileşme sağlamaktadır.

🔖

Cite This Article

Uzuner, B., Ketenci, S., Salbaş, E., Bilgici, A. (2025). Rapid Improvement of Fatigue and Sleep in Active Rheumatoid Arthritis with Anti-TNF Therapy: A Retrospective Observational Study. Çukurova Anestezi ve Cerrahi Bilimler Dergisi, Cilt: 8 Sayı: 4, 464–468. https://doi.org/10.36516/jocass.1818590

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (23)

  1. Aghdashi M, Seyedmardani S, Forouzin M, Azari H. Comparison of efficacy of Infliximab and Etanercept on Rheumatoid Arthritis patients. Rheumatology Research. 2021;6(1):35-42. [Crossref]
  2. Altowairqi AMA, Alanazi LAQ, Alhamrani MB, Almutairi AD, Alosaimi NS, Al Amoudi MH, et al. Structural Equation Modelling of Sleep Quality Determinants in Rheumatoid Arthritis: Pain, Inflammation and Psychological Factors. Journal of Advanced Trends in Medical Research. 2025;2(2):326-35. [Crossref]
  3. Mamasaidov A, Sakibaev K, Zhumabaeva S, Isakov U, Eshbaeva CA, Abdyllaev J, et al. Impact of Biological Therapies on Quality of Life in Rheumatoid Arthritis: A Narrative Review. Open Access Rheumatol. 2025;17:73-86. [Crossref]
  4. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-8. [Crossref]
  5. Radmanovic O, Janjic V, Veselinovic M, Kocovic A, Muric N, Dordic M, et al. The Impact of Insomnia on the Clinical Course and Treatment Outcomes of Rheumatoid Arthritis. Biomedicines. 2025;13(10). [Crossref]
  6. Singh G, Kumar V. Sleep Quality is Poor in Rheumatoid Arthritis Patients and Correlates with Anxiety, Depression, and Poor Quality of Life. Mediterr J Rheumatol. 2024;35(3):423-31. [Crossref]
  7. Siuchninska H, Minarowska A, Wasilewska E. Beyond Joints: Neuropsychiatric Benefits of TNF-alpha and IL-6 Inhibitors in Rheumatoid Arthritis-Narrative Review. Int J Mol Sci. 2025;26(17). [Crossref]
  8. Khadour FA, Khadour YA, Ebrahem BM. A qualitative survey on factors affecting depression and anxiety in patients with rheumatoid arthritis: a cross-sectional study in Syria. Sci Rep. 2024;14(1):11513. [Crossref]
  9. Kozlowska KA, Baczyk G. Sleep quality and fatigue level, clinical and demographic factors in women with rheumatoid arthritis. Front Glob Womens Health. 2025;6:1534447. [Crossref]
  10. Druce KL, Jones GT, Macfarlane GJ, Basu N. Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2015;54(6):964-71. [Crossref]
  11. Pope JE. Management of Fatigue in Rheumatoid Arthritis. RMD Open. 2020;6(1). [Crossref]
  12. Luyster FS, Chasens ER, Wasko MCM, Dunbar-Jacob J. Sleep Quality and Functional Disability in Patients with Rheumatoid Arthritis. Journal of Clinical Sleep Medicine. 2011;07(01):49-55. [Crossref]
  13. Shim J, Dean LE, Karabayas M, Jones GT, Macfarlane GJ, Basu N. Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis. Rheumatology (Oxford). 2020;59(11):3408-14. [Crossref]
  14. Moral K, Bilgin E, Karadağ Ö, Akdoğan A, Apraş Bilgen Ş, Kiraz S, et al. Sleep quality and blood pressure variability after anti-TNF-α treatment in axial spondyloarthritis patients: A prospective preliminary study. Ulusal Romatoloji Dergisi. 2025. [Crossref]
  15. Hammam N, Gamal RM, Rashed AM, Elfetoh NA, Mosad E, Khedr EM. Fatigue in Rheumatoid Arthritis Patients: Association With Sleep Quality, Mood Status, and Disease Activity. Reumatol Clin (Engl Ed). 2020;16(5 Pt 1):339-44. [Crossref]
  16. Altunel KilinÇ E, TÜRk İ. The Impact of Higher Disease Activity on Sleep Quality in Patients with Rheumatoid Arthritis. Namık Kemal Tıp Dergisi. 2025;13(3):200-8. [Crossref]
  17. Stein KD, Jacobsen PB, Blanchard CM, Thors C. Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage. 2004;27(1):14-23. [Crossref]
  18. Ağargün MY, Kara H, Anlar Ö. The Validity and Reliability of the Pittsburgh Sleep Quality Index. Turkish Journal of Psychiatry. 1996;7(2):107-11.
  19. Hisli N. A Study on the Validity of the Beck Depression Inventory. Journal of Psychology. 1988;22(3):118-26.
  20. Ozcan E, Yilmaz O, Tutoglu A, Bodur H. Validity and reliability of the Turkish version of the Health Assessment Questionnaire for the Spondyloarthropathies. Rheumatol Int. 2012;32(6):1563-8. [Crossref]
  21. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27(1):261-3.
  22. Bechman K, Sin FE, Ibrahim F, Norton S, Matcham F, Scott DL, et al. Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial. RMD Open. 2018;4(1):e000676. [Crossref]
  23. Liu N, Yan W, Su R, Zhang L, Wang X, Li Z, et al. Research progress on rheumatoid arthritis-associated depression. Front Behav Neurosci. 2022;16:992223. [Crossref]